Literature DB >> 20370773

Complement activation in emergency department patients with severe sepsis.

John G Younger1, David O Bracho, Hangyul M Chung-Esaki, Moonseok Lee, Gurpreet K Rana, Ananda Sen, Alan E Jones.   

Abstract

OBJECTIVES: This study assessed the extent and mechanism of complement activation in community-acquired sepsis at presentation to the emergency department (ED) and following 24 hours of quantitative resuscitation.
METHODS: A prospective pilot study of patients with severe sepsis and healthy controls was conducted among individuals presenting to a tertiary care ED. Resuscitation, including antibiotics and therapies to normalize central venous and mean arterial pressure (MAP) and central venous oxygenation, was performed on all patients. Serum levels of Factor Bb (alternative pathway), C4d (classical and mannose-binding lectin [MBL] pathway), C3, C3a, and C5a were determined at presentation and 24 hours later among patients.
RESULTS: Twenty patients and 10 healthy volunteer controls were enrolled. Compared to volunteers, all proteins measured were abnormally higher among septic patients (C4d 3.5-fold; Factor Bb 6.1-fold; C3 0.8-fold; C3a 11.6-fold; C5a 1.8-fold). Elevations in C5a were most strongly correlated with alternative pathway activation. Surprisingly, a slight but significant inverse relationship between illness severity (by sequential organ failure assessment [SOFA] score) and C5a levels at presentation was noted. Twenty-four hours of structured resuscitation did not, on average, affect any of the mediators studied.
CONCLUSIONS: Patients with community-acquired sepsis have extensive complement activation, particularly of the alternative pathway, at the time of presentation that was not significantly reversed by 24 hours of aggressive resuscitation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370773      PMCID: PMC2918899          DOI: 10.1111/j.1553-2712.2010.00713.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  18 in total

1.  Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.

Authors:  R F Guo; M Huber-Lang; X Wang; V Sarma; V A Padgaonkar; R A Craig; N C Riedemann; S D McClintock; T Hlaing; M M Shi; P A Ward
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Systemic and lung physiological changes in rats after intravascular activation of complement.

Authors:  J G Younger; N Sasaki; J Delgado; A C Ko; T X Nghiem; M D Waite; G O Till; P A Ward
Journal:  J Appl Physiol (1985)       Date:  2001-06

3.  Chronological changes in the complement system in sepsis.

Authors:  H Nakae; S Endo; K Inada; M Yoshida
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Protective effects of C5a blockade in sepsis.

Authors:  B J Czermak; V Sarma; C L Pierson; R L Warner; M Huber-Lang; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

5.  Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.

Authors:  Ines J Laudes; Jeffrey C Chu; Sujata Sikranth; Markus Huber-Lang; Ren-Feng Guo; Niels Riedemann; J Vidya Sarma; Alvin H Schmaier; Peter A Ward
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

6.  Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.

Authors:  P F Weinberg; M A Matthay; R O Webster; K V Roskos; I M Goldstein; J F Murray
Journal:  Am Rev Respir Dis       Date:  1984-11

7.  C5a induces tissue factor activity on endothelial cells.

Authors:  K Ikeda; K Nagasawa; T Horiuchi; T Tsuru; H Nishizaka; Y Niho
Journal:  Thromb Haemost       Date:  1997-02       Impact factor: 5.249

8.  Functional roles for C5a receptors in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Brian A Nadeau; Danielle E Day; Markus Huber-Lang; Charles R Mackay; Firas S Zetoune; Norma P Gerard; Katherine Cianflone; Jörg Köhl; Craig Gerard; J Vidya Sarma; Peter A Ward
Journal:  Nat Med       Date:  2008-05-04       Impact factor: 53.440

9.  Increased C5a receptor expression in sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Thomas A Neff; Ines J Laudes; Katie A Keller; Vidya J Sarma; Maciej M Markiewski; Dimitrios Mastellos; Christoph W Strey; Carl L Pierson; John D Lambris; Firas S Zetoune; Peter A Ward
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 10.  The dark side of C5a in sepsis.

Authors:  Peter A Ward
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

View more
  12 in total

Review 1.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

2.  The effect of human complement C3 protein applied at different times in treatment of polymicrobial sepsis.

Authors:  Yujie Yuan; Jianan Ren; Guosheng Gu; Shougen Cao; Jieshou Li
Journal:  Inflamm Res       Date:  2012-02-16       Impact factor: 4.575

3.  Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis.

Authors:  Lin Zou; Yan Feng; Yan Li; Ming Zhang; Chan Chen; Jiayan Cai; Yu Gong; Larry Wang; Joshua M Thurman; Xiaobo Wu; John P Atkinson; Wei Chao
Journal:  J Immunol       Date:  2013-10-23       Impact factor: 5.422

4.  Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Authors:  Erin C Conrad; Yueh-Ya Hsu; David M Bortz; John G Younger
Journal:  J Innate Immun       Date:  2013-01-11       Impact factor: 7.349

5.  Dynamics of human complement-mediated killing of Klebsiella pneumoniae.

Authors:  Christina M Nypaver; Margaret M Thornton; Suellen M Yin; David O Bracho; Patrick W Nelson; Alan E Jones; David M Bortz; John G Younger
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-11       Impact factor: 6.914

6.  Complement c5a generation by staphylococcal biofilms.

Authors:  Ashley E Satorius; Jacob Szafranski; Derek Pyne; Mahesh Ganesan; Michael J Solomon; Duane W Newton; David M Bortz; John G Younger
Journal:  Shock       Date:  2013-04       Impact factor: 3.454

7.  Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma.

Authors:  Chimdiya Onwukwe; Nuzhat Maisha; Mark Holland; Matt Varley; Rebecca Groynom; DaShawn Hickman; Nishant Uppal; Andrew Shoffstall; Jeffrey Ustin; Erin Lavik
Journal:  Bioconjug Chem       Date:  2018-07-09       Impact factor: 4.774

8.  Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.

Authors:  Morten Hedetoft; Martin Bruun Madsen; Cecilie Bo Hansen; Ole Hyldegaard; Peter Garred
Journal:  J Innate Immun       Date:  2021-12-14       Impact factor: 7.111

9.  Properdin levels in human sepsis.

Authors:  Cordula M Stover; John McDonald; Simon Byrne; David G Lambert; Jonathan P Thompson
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

10.  Complement depletion deteriorates clinical outcomes of severe abdominal sepsis: a conspirator of infection and coagulopathy in crime?

Authors:  Jianan Ren; Yunzhao Zhao; Yujie Yuan; Gang Han; Weiqin Li; Qian Huang; Zhihui Tong; Jieshou Li
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.